The in vitro activity of a new quinolone, AM-1091 [7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid hydrochloride], was compared with those of ciprofloxacin, ofloxacin, beta-lactams, and gentamicin. AM-1091 inhibited 90% of the isolates of the family Enterobacteriaceae at s0.12 ,ug/ml. For many species AM-1091 was 2-fold more active than ciprofloxacin and 2-to 32-fold more active than ofloxacin. It inhibited Enterobacter, Citrobacter, and Klebsiella species resistant to ceftazidime and gentamicin. Ninety percent of Pseudomonas aeruginosa isolates were inhibited by 0.5 ,ug/ml, so for this species AM-1091 was twofold less active than ciprofloxacin. AM-1091 was more active against Pseudomonas cepacia and Xanthomonas maltophilia, inhibiting isolates resistant to imipenem and gentamicin. Most Haemophilus influenzae, Neisseria gonorrhoeae, Neisseria meningitidis, and Branhamella catarrhalis isolates were inhibited by .0.06 ,ug/ml. The MICs for 90% of Staphylococcus aureus, Staphylococcus epidermidis, and Enterococcusfaecalis isolates were 0.06, 0.06, and 2 ,ug/ml, respectively. AM-1091 inhibited hemolytic streptococci and Streptococcus pneumoniae at 0.25 ,ug/mI and was more active than ciprofloxacigor ofloxacin against gram-positive species. AM-1091 inhibited 90% of the Bactepoides species at 0.5 ,ug/ml. he frequency of spontaneous resistance was <10-10 for most organisms, but resistant strains could be selected by repeated subculturing. Although AM-1091 had lower in vitro activity at lH 5.5 and in the presence of high concentrations of Mg2+, it still inhibited most organisms at .0.5 ,ug/ml under these conditions. AM-1091 rapidly killed Escherichia coli and P. aeruginosa and had a prolonged postantibiotic suppressive effect on these bacteria.
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There has been major interest in the synthesis of novel quinolones. Many compounds of the new quinolone class have excellent in vitro activity against members of the family Enterobacteriaceae and Pseudomonas aeruginosa, but activity against streptococcal and enterococcal species is borderline, and that against anaerobic species is inadequate (3, 10) . Compound AM-1091 is a new quinolone with the chemical structure 7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid hydrochloride (Fig. 1) . We compared the activity of AM-1091 with those of other quinolones, ceftazidime, imipenem, and gentamicin and determined the effect of various assay conditions on its in vitro activity.
MATERIALS AND METHODS
Drugs and isolates. AM-1091 was a gift from Kyorin Pharmaceutical Co., Ltd., Tokyo, Japan. All other agents were obtained from their respective manufacturers. Quinolones were prepared as described previously (6) . Fresh dilutions of all compounds used were prepared daily. Bacterial isolates were obtained from patients hospitalized at The Presbyterian Hospital, New York, N.Y. Only one isolate from each patient was tested to avoid mt.ltiple copies of the same strain. Some isolates came from patients who had been subjects in an investigation of the efficacy and safety of new quinolones.
Antimicrobial susceptibility tests. Antimicrobial susceptibility was measured by an agar dilution method with Mueller-Hinton agar in accordance with the guidelines of the National Committee for Clinical Laboratory Standards (8) . A replicating spot device applied 104 CFU prepared by dilution of fresh overnight broth. Broth dilutions were performed with 5 x 105 CFU in 1-ml tubes. The MIC was defined as the lowest concentration of antimicrobial agent that inhibited the development of visible growth on agar or in the tubes after 18 to 20 h of incubation. The MBC was determined by plating 0.01 ml from clear tubes to agar plates. The MBC was defined as the concentration at which there was a 99.9% reduction in CFU by the method of Pearson et al. (9) , considering normal pipetting error. The effects of serum, urine, pH, and ion changes in the medium were determined as described previously (6) . All assays were run simultaneously.
The susceptibilities of Neisseria, Branhamella, and Haemophilus spp. were determined with chocolate MuellerHinton agar in the presence of 5% CO2. The susceptibilities of streptococci were determined with Mueller-Hinton agar supplemented with 5% sheep blood. Activity against anaerobic species was determined with brucella agar supple- C. Ji-eundii, P. aeru-iginosa, and Serratia inarcescens. Table   3 shows the effect of various concentrations of cations on the (5) . The MICs and MBCs were determined for isolates of E. coli, provided by H. Nakaido, in which either OmpC or OmpF was deficient. The MIC and MBC for both the OmpF+C+ strain and the OmpF+C-strain were 0.008 and 0.015 ,ug/ml, respectively. The MIC and MBC for the OmpF-C+ strain were 0.015 and 0.015 ,ug/ml, respectively. When P. aeruginosa 799K (11) was used, the MIC for the permeable mutant was 0.06 p.g/ml, as compared with 0.25 p.g/ml for the parent strain.
Development of resistance to AM-1091. The development of spontaneous resistance to AM-1091 was determined for two isolates each of E. coli, K. pneumoniae, C. freundii, E. cloacae, S. marcescens, P. aeruginosa, S. aureus, and E. faecalis. For all of these organisms the frequency of resistance to a concentration eight times the MIC was <10-9, and in most situations it was <10-°.
Repeated subculturing in the presence of AM-1091 resulted in increases in MICs. The MIC for E. coli 4017 increased from 0.004 to 0.03 ,ig/ml, that for K. pneumoniae increased from 0.015 to 2 jig/ml, that for P. aeruginosa increased from 0.06 to 2 ,ug/ml, and that for S. aureus increased from 0.015 to 0.03 ,ug/ml. The increase in MICs was stable. MICs of ciprofloxacin, ofloxacin, and norfloxacin also increased (Table 5) . These isolates did not show cross-resistance to ureido-penicillins or aminothiazoly-cephalosporins or aminoglycosides. Susceptibilities to tetracycline and chloramphenicol were not determined.
Killing curves and PAE. Exposure of a P. aeruginosa strain for which the AM-1091 MIC was 0.25 ,ug/ml to the MIC for 15, 30, and 60 min produced 1.15-, 1.4-, and 2.23-log1o reductions in CFU, respectively. A 60-min exposure of P. aeruginosa to a concentration of AM-1091 eight times the MIC in urine produced a 4.1-log1o reduction in CFU. AM-1091 at eight times the MIC produced a PAE of 5 h for P. aeruginosa and a PAE of 6 h for E. coli in Mueller-Hinton broth (pH 7.4) with an Mg2+ concentration similar to that in human serum. Similarly, in urine AM-1091 at a concentration 16 times the MIC produced a PAE of 5 h for both E. coli and P. aeruginosa. DISCUSSION AM-1091 differs from a number of the currently available fluoroquinolone compounds. It possesses at position N-1 a cyclopropyl group, but the piperazinyl group at position C-7 has been replaced by a 3-amino-1-pyrrolidinyl group, and at position C-8 there is a chlorine. It would appear from this study that these structural modifications of the quinolone compound have resulted in enhanced antibacterial activity against gram-positive bacteria and anaerobic species. For example, the MIC90 of AM-1091 for methicillin-susceptible and methicillin-resistant S. aureus isolates was 0.06 ,.g/ml, as compared with 1 to 2 jig/ml for ciprofloxacin. The activity of AM-1091 against streptococci and S. pneumoniae was also better than that of the other quinolone agents currently available (3, 10) . In this study B. fragilis and other Bacteroides and Clostridium spp. were also inhibited by <1 ,ug/ml, in contrast to the much higher concentrations required for other agents. The increase in activity against the grampositive species, particularly streptococci, and against anaerobes has not resulted in a loss of activity against members of the family Enterobacteriaceae and P. aeruginosa, as occurred with CI-934 (7), since these organisms were inhibited at concentrations lower than or similar to those of the currently most active quinolone, ciprofloxacin. Ciprofloxacin remains the most active agent tested against P. aeruginosa on an overall basis, although some strains were inhibited by a twofold-lower concentration of AM-1091. AM-1091 inhibited imipenem-, ceftazidime-, amikacin-, and piperacillin-resistant P. aerllginosa. It was more active than other quinolones or other agents against X. maltophilia and P. cepacia. Of particular note was the excellent activity against the Acinetobacter spp., most of which were resistant to gentamicin and ceftazidime and for which the MIC90s of both ciprofloxacin and ofloxacin were 1 ,ug/ml.
Like the activity of other quinolones (6) , the activity of AM-1091 was reduced at pH 5.5, but its activity was minimally decreased by high Mg2" concentrations. At concentrations anticipated in urine or in serum it showed rapid killing and prolonged PAE even for pathogens for which the MICs were higher. These results are similar to what we have shown for ciprofloxacin and compound T-3262 (A-60969) (1, 4).
The frequency of spontaneous resistance to AM-1091 was low, but isolates for which MICs were higher could be selected by repeated passage in the drug. This resistance was stable, although the MICs of AM-1091 were appreciably lower than the MICs of ciprofloxacin, ofloxacin, and norfloxacin for these organisms.
Because of its excellent in vitro activity, AM-1091 certainly should undergo further evaluation to determine its pharmacology and potential for clinical use.
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